"Dipyridamole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
| Descriptor ID |
D004176
|
| MeSH Number(s) |
D03.383.742.175
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dipyridamole".
Below are MeSH descriptors whose meaning is more specific than "Dipyridamole".
This graph shows the total number of publications written about "Dipyridamole" by people in this website by year, and whether "Dipyridamole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dipyridamole" by people in Profiles.
-
Recent advances in drug repurposing using machine learning. Curr Opin Chem Biol. 2021 12; 65:74-84.
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Autoantibodies May Drive COVID-19 Blood Clots. JAMA. 2021 02 02; 325(5):425.
-
Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients. Curr Pharm Des. 2021; 27(6):866-875.
-
Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? Emerg Microbes Infect. 2020 Dec; 9(1):1514-1522.
-
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27381-27387.
-
New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. JCI Insight. 2020 07 23; 5(14).
-
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. Med Hypotheses. 2020 Oct; 143:110051.
-
A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. J Infect Dis. 2020 04 27; 221(10):1598-1606.